– Jeito Capital closed its second fund, Jeito II, at $1.2 billion (over €1 billion), exceeding its target
– Total assets under management have tripled to €1.6 billion, following Jeito I ($630 million / €534 million in 2021)
– Strengthens Jeito’s position as a leading independent European Biopharma investor
– Jeito II strategy continues Jeito I approach: invest in 15–20 high-potential clinical-stage Biopharma companies
– Focus primarily on Europe, targeting breakthrough therapies for severe diseases with unmet medical needs
– Capital already deployed in key therapeutic areas: obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology, and cardio-metabolic diseases
– Fund backed by a diversified global investor base: sovereign funds, pharma companies, insurers, pension funds, family offices, foundations, and banks
– Strong re-up rate and new investor demand reflect confidence in Jeito’s strategy and market opportunity
– Jeito II signals strength of the European Biopharma ecosystem
– Rafaèle Tordjman, MD, PhD, Founder and CEO, highlights milestone fundraising and investor trust
– Sabine Dandiguian, Managing Partner, emphasizes disciplined strategy and focus on high-impact innovation
